Department of Science and Mathematics, Texas A&M University San Antonio, San Antonio, Texas, USA.
Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Am J Primatol. 2020 Dec;82(12):e23196. doi: 10.1002/ajp.23196. Epub 2020 Sep 24.
Disruption of microbial communities within human hosts has been associated with infection, obesity, cognitive decline, cancer risk and frailty, suggesting that microbiome-targeted therapies may be an option for improving healthspan and lifespan. The objectives of this study were to determine the feasibility of delivering fecal microbiota transplants (FMTs) to marmosets via oral gavage and to evaluate if alteration of the gut microbiome post-FMT could be achieved. This was a prospective study of marmosets housed at the Barshop Institute for Longevity and Aging Studies in San Antonio, Texas. Eligible animals included healthy young adult males (age 2-5 years) with no recent medication use. Stool from two donors was combined and administered in 0.5 ml doses to five young recipients once weekly for 3 weeks. Safety outcomes and alterations in the gut microbiome composition via 16S ribosomal RNA sequencing were compared at baseline and monthly up to 6 months post-FMT. Overall, significant differences in the percent relative abundance was seen in FMT recipients at the phylum and family levels from baseline to 1 month and baseline to 6 months post-FMT. In permutational multivariate analysis of variance analyses, treatment status (donor vs. recipient) (p = .056) and time course (p = .019) predicted β diversity (p = .056). The FMT recipients did not experience any negative health outcomes over the course of the treatment. FMT via oral gavage was safe to administer to young adult marmosets. The marmoset microbiome may be altered by FMT; however, progressive changes in the microbiome are strongly driven by the host and its baseline microbiome composition.
破坏宿主内的微生物群落与感染、肥胖、认知能力下降、癌症风险和虚弱有关，这表明针对微生物组的治疗方法可能是改善健康寿命和寿命的一种选择。本研究的目的是确定通过口服灌胃向狨猴递送粪便微生物群移植（FMT）的可行性，并评估 FMT 后肠道微生物组是否会发生改变。这是一项在德克萨斯州圣安东尼奥的巴肖普长寿与衰老研究所进行的狨猴的前瞻性研究。符合条件的动物包括没有近期用药史的健康年轻成年雄性（2-5 岁）。将来自两名供体的粪便混合并以 0.5ml 剂量每周一次给予五名年轻受者，连续 3 周。在 FMT 前和每月一次直至 6 个月后，通过 16S 核糖体 RNA 测序比较安全性结果和肠道微生物组组成的变化。总体而言，FMT 受者在门和科水平的相对丰度百分比在 FMT 前至 1 个月和 FMT 前至 6 个月时均有显著差异。在置换多元方差分析中，治疗状态（供体与受者）（p=0.056）和时间进程（p=0.019）预测了β多样性（p=0.056）。在治疗过程中，FMT 受者没有出现任何负面健康结果。通过口服灌胃向年轻成年狨猴给予 FMT 是安全的。FMT 可能会改变狨猴的微生物组；然而，微生物组的渐进变化主要由宿主及其基线微生物组组成决定。
